Background: SYK gene regulates the expression of SYK kinase (Spleen tyrosine kinase), an important non-receptor protein-tyrosine kinase for immunological receptor-mediated signaling, which is also considered a tumor growth metastasis initiator. An onco-informatics analysis was adopted to evaluate the expression and prognostic value of the SYK gene in colorectal cancer (CRC), the third most fatal cancer type; of late, it may be a biomarker as another targeted site for CRC. In addition, identify the potential phytochemicals that may inhibit the overexpression of the SYK kinase protein and minimize the human CRC. Materials & Methods: The differential expression of the SYK gene was analyzed using several transcriptomic databases, including Oncomine, UALCAN, GENT2, and GEPIA2. The server cBioPortal was used to analyze the mutations and copy number alterations, whereas GENT2, Gene Expression Profiling Interactive Analysis (GEPIA), Onco-Lnc, and PrognoScan were used to examine the survival rate. The protein-protein interaction network of SYK kinase and its co-expressed genes was conducted via Gene-MANIA. Considering the SYK kinase may be the targeted site, the selected phytochemicals were assessed by molecular docking using PyRx 0.8 packages. Molecular interactions were also observed by following the Ligplot+ version 2.2. YASARA molecular dynamics simulator was applied for the post-validation of the selected phytochemicals. Results: Our result reveals an increased level of mRNA expression of the SYK gene in colorectal adenocarcinoma (COAD) samples compared to those in normal tissues. A significant methylation level and various genetic alterations recurrence of the SYK gene were analyzed where the fluctuation of the SYK alteration frequency was detected across different CRC studies. As a result, a lower level of SYK expression was related to higher chances of survival. This was evidenced by multiple bioinformatics platforms and web resources, which demonstrated that the SYK gene can be a potential biomarker for CRC. In this study, aromatic phytochemicals, such as kaempferol and glabridin that target the macromolecule (SYK kinase), showed higher stability than the controls, and we have estimated that these bioactive potential phytochemicals might be a useful option for CRC patients after the clinical trial. Conclusions: Our onco-informatics investigation suggests that the SYK gene can be a potential prognostic biomarker of CRC. On the contrary, SYK kinase would be a major target, and all selected compounds were validated against the protein using in-silico drug design approaches. Here, more in vitro and in vivo analysis is required for targeting SYK protein in CRC.

The mechanisms involved in immune responses to cancer have been extensively studied for several decades, and considerable attention has been paid to harnessing the immune system’s therapeutic potential. Cancer immunotherapy has established itself as a promising new treatment option for a variety of cancer types. Various strategies including cancer vaccines, monoclonal antibodies (mAbs), adoptive T-cell cancer therapy and CAR T-cell therapy have gained prominence through immunotherapy. However, the full potential of cancer immunotherapy remains to be accomplished. In spite of having startling aspects, cancer immunotherapies have some difficulties including the inability to effectively target cancer antigens and the abnormalities in patients’ responses. With the advancement in technology, this system has changed the genome-based immunotherapy process in the human body including the generation of engineered T cells. Due to its high specificity, CRISPR-Cas9 has become a simple and flexible genome editing tool to target nearly any genomic locus. Recently, the CD19-mediated CAR T-cell (chimeric antigen receptor T cell) therapy has opened a new avenue for the treatment of human cancer, though low efficiency is a major drawback of this process. Thus, increasing the efficiency of the CAR T cell (engineered T cells that induce the chimeric antigen receptor) by using CRISPR-Cas9 technology could be a better weapon to fight against cancer. In this review, we have broadly focused on recent immunotherapeutic techniques against cancer and the use of CRISPR-Cas9 technology for the modification of the T cell, which can specifically recognize cancer cells and be used as immune-therapeutics against cancer.

Purpose: Cellulase, due to its massive applicability, has been used in various industrial processes such as biofuels (bioethanol, triphasic biomethanation), agricultural and plant waste management, chiral separation, and ligand binding studies. The finding of a novel cellulase-producing bacterium will benefit the industries, which rely on yeast to produce cellulase in fermentation technology, because bacteria can easily be manipulated and fermented cost-effectively.Methods: Cellulase enzyme-secreting bacteria were isolated from different regions of the world’s largest mangrove forests, Sundarbans in Bangladesh. Biochemical, morphological, and 16S rRNA identification protocol was followed to precisely characterize the bacterial strains.Result: We have determined that the strain T2-D2 (Bacillussp.), E1-PT (Pseudomonassp.), and D1-PT (Pseudomonassp.) showed maximum endoglycolytic and strain C1-BT (Bacillussp.), E1-BT (Bacillussp.), and T-4 (E) showed relatively higher exoglycolytic activity during the test. So, it can be easily cultured at a normal temperature (97.7–99.5 °F). On the one hand, T2-D2 (Bacillussp.) and E1-PT (Pseudomonassp.) have shown the highest growth rate at pH 7 as it was neither acidic nor basic.Conclusion: It was concluded that the strain T2-D2 (Bacillussp.) and E1-PT (Pseudomonassp.) would be our target cellulolytic strains wherein the experimental isolates belonged to the Enterobacteriaceae, Psuedomonacea, Bacillacea, and Morganellacea family.

The mechanisms involved in immune responses to cancer have been extensively studied for several decades and, considerable attention has been paid to harnessing the immune system's therapeutic potential. Cancer immunotherapy has established itself as a promising new treatment option for a variety of cancer types. Various strategies including cancer vaccines, monoclonal antibodies (mAbs), adoptive T-cell-cancer therapy and immune test therapy have gained prominence through immunotherapy. However, it remains to be accomplished the full potential of cancer immunotherapy. In spite of having startling aspects, the cancer immunotherapies have some difficulties including the inability to effectively targeting the cancer antigens and the abnormalities in patient response. With the advancement of technology, this system has changed the genome-based immunotherapy process in the human body including generation of engineered T cells. Due to its high specificity, CRISPR-Cas9 has become a simple and flexible genome-editing tool to target nearly any genomic locus. Recently, the CD19-mediated CAR-T cell (chimeric antigen receptor T cell) therapy has opened a new avenue for the treatment of human cancer, though low efficiency is a major drawback of this process. Thus, increasing the efficiency of the CAR-T cell (engineered T cells that induce the chimeric antigen receptor) by using CRISPR-Cas9 technology could be a better weapon to fight against the cancer. In this review, we have broadly focused on the use of CRISPR-Cas9 technology for the modification of the T-cell, which can specifically recognize cancer cells and be used as immune therapeutics against cancer. We have also demonstrated the other potential strategies for the treatment of cancer.

Background: Since the 2022 outbreak, the number of Monkeypox cases worldwide has been increasing at an alarming rate. As of August 2024, approximately 99,000 people have been infected with the virus. The severity of this situation is further highlighted by the World Health Organization's (WHO) classification of the Mpox virus as a Public Health Emergency of International Concern (PHEIC) due to the increased fatality rate of approximately 3.6% in clade I. Objectives: Targeting the virus's membrane-bound, enveloped, and extracellular proteins, our goal was to computationally develop and assess a broad-spectrum multi-epitope vaccine that elicits humoral and adaptive immune responses against Monkeypox virus (MPXV) infection. Methods: During an outbreak, a pan-genome-based reverse vaccinology approach can offer rapid, practical solutions to enduring problems in experimental vaccine design. The method involved screening 16 monkeypox genomes to identify viral targets, from which viral proteins were selected based on their antigenicity, location, and solubility. Immunoinformatics methods and algorithms were used to extract the proteins’ putative T-cell and B-cell epitopes, which were combined to form several vaccine constructions. The tertiary structure of the chimeric vaccine construct's interaction with Toll-like receptor 4 (TLR4) was thoroughly assessed using the advanced techniques of molecular docking and molecular dynamics simulation. Results: A pan-genomic analysis identified 80 core genes, which were then screened for proteins suitable for epitope-based vaccine design. From four of these selected proteins, T-cell and B-cell epitopes were extracted to create four distinct vaccine constructs. Appropriate adjuvants and linkers were incorporated into each construct to enhance its potential efficacy. Stability and immunogenicity analyses of each vaccine design yielded promising results. These findings suggest that the vaccine constructs could be effective in preventing monkeypox, warranting further experimental validation and supporting the application of similar strategies to combat other viral illnesses.